Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Phase 2 Completed 23 enrolled Eisai Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) to determine whether each cohort warrants further investigation.

Timeline

Start: 2018-04-17
Primary completion: 2021-01-07
Completion: 2022-01-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eribulin	Small molecule	1.4 mg/m2	Intravenous

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Summary

Timeline

Drugs

Indications